Palladia (Toceranib): Approved Canine Mast Cell Tumor Targeted Therapy

Palladia is an FDA-approved prescription veterinary tyrosine kinase inhibitor for treatment of Patnaik grade II or III recurrent canine cutaneous mast cell tumors, with or without regional lymph-node involvement, under the conditions in its label.

Therapy class: Prescription oral antineoplastic; multi-target receptor tyrosine kinase inhibitor

Form and route: Film-coated oral tablets

Toceranib, supplied as toceranib phosphate

Toceranib inhibits several split-kinase receptor tyrosine kinases implicated in tumor-cell signaling and pathologic angiogenesis. FDA labeling and Zoetis describe antiproliferative and antiangiogenic actions; the approved indication, not an unrestricted mechanism claim, defines on-label use.

Manufacturer positioning: Zoetis presents Palladia as an antiangiogenic and antiproliferative therapy developed for canine cancer. Directory should retain the exact approved mast cell tumor indication and avoid implying approval for every tumor for which toceranib may be discussed off label.

The intended treatment outcome, response measurement, monitoring schedule and stopping rules should be written for the individual dog before the first tablet is given.

Use follows tissue diagnosis and a veterinary review of tumor status, blood counts, organ function, gastrointestinal health, concurrent medicines and household ability to follow hazardous-drug precautions.

FDA/EMA/GB authorisation supports only the conditions in the current regional label. Off-label tumor uses, response expectations and combination plans are separate veterinarian-led decisions and must not be described as approved indications.

The label describes potentially serious gastrointestinal, blood-count, vascular and other adverse effects. Contact the prescribing clinic promptly for appetite loss, vomiting, diarrhea, black or bloody stool, unusual bruising or bleeding, weakness or fever; follow its emergency thresholds.

The prescribing veterinarian must review all NSAIDs, corticosteroids, anticoagulants, chemotherapy, supplements and other drugs. Do not split, crush or change tablets or timing unless the label and veterinary team expressly direct it.

United States: FDA-approved prescription animal drug, NADA 141-295, approved in 2009 for the labeled canine mast cell tumor indication. European Union: centrally authorised veterinary medicinal product, EMEA/V/C/000150. Great Britain: currently authorised POM-V product under Zoetis UK registrations. Local indication wording and product information must be checked because U.S., EU and GB labels are not interchangeable.

Verified current regulatory records: United States, European Union/EEA and Great Britain; Northern Ireland follows the EU product authorisation. Do not extrapolate these labels to other regions without checking the relevant national regulator.

Veterinary monitoring should follow the current regional label and the individual plan. Official owner materials identify physical examinations plus CBC, serum chemistry, urinalysis, occult-blood assessment, weight and temperature as relevant follow-up elements. Monitor gastrointestinal signs, stool blood/black stool, appetite, weight, blood counts, renal values, albumin/phosphorus and signs of edema or thromboembolism. Handling and biological-waste precautions apply; owners must not independently split, restart, reduce or stop treatment except under prescriber instructions and label stop-and-call rules.